Catalent Appoints Senior Vice President and General Counsel
14 Oktober 2014 - 3:05PM
Business Wire
Catalent Pharma Solutions, the leading global provider of
advanced delivery technologies and development solutions for drugs,
biologics and consumer health products, today announced it has
appointed Steven Fasman as Senior Vice President and General
Counsel, effective immediately.
John Chiminski, President and CEO, Catalent Pharma Solutions
said, “I am delighted that Steven Fasman has joined Catalent. He is
widely respected as a talented lawyer with a proven record of
leadership in results-focused environments, making him the ideal
person for this important position on Catalent’s executive
leadership team.”
Steven Fasman joins Catalent with an accomplished legal career
and extensive experience in a broad range of industries in both
private practice and corporate in-house roles. Most recently he
served as Executive Vice President of Law at MacAndrews &
Forbes Holdings, Inc., a private investment firm with interests in
bio-technology, consumer products, banking, media, e-commerce, and
other businesses. As the senior lawyer in the MacAndrews &
Forbes legal department, he oversaw all legal aspects pertaining to
its business transactions, including mergers and acquisitions,
intellectual property, SEC filings, regulatory issues, and
commercial deals.
From 2008 to 2011, he concurrently served as the Chief Legal
Officer and Chief Compliance Officer for M&F Worldwide Corp., a
diversified, NYSE-listed company with $1.9 billion in annual
revenue.
Mr. Fasman spent his early career at the top-tier, New York City
law firm of Paul, Weiss, Rifkind, Wharton & Garrison, where he
focused on domestic and international litigation and regulatory
proceedings.
A law-graduate of Yale University with a bachelor’s degree in
math from Princeton University, Mr. Fasman is currently President
and a trustee of the Jewish Board of Family & Children’s
Services in New York City. He is married with two children.
Notes for editors:
About Catalent
Catalent Pharma Solutions, is the leading global provider of
advanced delivery technologies and development solutions for drugs,
biologics and consumer health products. With over 80 years serving
the industry, Catalent has proven expertise in bringing more
customer products to market faster, enhancing product performance
and ensuring reliable clinical and commercial product supply.
Catalent employs approximately 8,000 people, including over 1,000
scientists, at nearly 30 facilities across 5 continents and in
fiscal 2014 generated more than $1.8 billion in annual revenue.
Catalent is headquartered in Somerset, N.J. For more information,
visit www.catalent.com.
More products. Better treatments. Reliably supplied.™
For Catalent Pharma SolutionsChris Halling, +44 (0)7580
041073chris.halling@catalent.comorRichard Kerns, +44 (0)161 728
5880richard@nepr.eu
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024